The humanized monoclonal antibody targeting the IL-6 receptor tocilizumab (TCZ) not only exerts protective effects in sepsis-induced AKI and improves patient survival rates [201] but also delays cellular senescence in rhabdomyolysis-associated AKI by inhibiting the IL-6/GATA2/SERPINE1 pathway and down-regulates the mRNA and protein levels of cell cycle regulatory proteins P53 and P21 [202]. This evidence concerns the gene TP53 and acute kidney injury.